March 7 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* Provides corporate update
* Says is evaluating strategic merger and acquisition opportunities to grow its
commercial product portfolio
* Expects to receive feedback from FDA in Q2 on clinical,regulatory
requirements for development of flexicaine
* Will be finalizing its strategy for commercialization of pliaglis which is
approved for sale in Canada,US
Source text for Eikon
Further company coverage CTX.TO